April 19, 2024
Ocular Hypertension Articles
March 1, 2024
Travoprost Implant Noninferior to Twice-daily Timolol 0.5% Drops
By Conni Koury, contributing writer
December 1, 2023
Trials in Focus: The COAST Trial of Selective Laser Trabeculoplasty
By Tony Realini, MD, MPH
December 1, 2023
Fixed High-energy SLT Superior to Standard Titrated Protocol for IOP Lowering
By Conni Koury, contributing writer
September 1, 2023
First-in-Class, Dual-MOA Small-molecule Glaucoma Treatment Met Primary Endpoints in Phase 2a Trial
By Conni Koury, contributing writer
June 1, 2023
Iyuzeh Shows Similar IOP Lowering to Xalatan in Phase 3 Study
By Rochelle Nataloni, contributing writer
March 1, 2023
Visiox Submits NDA for First Once-daily Brimonidine
By Conni Koury, contributing writer
March 1, 2023
Six-year Results from LiGHT Trial Confirm SLT's Safety, Efficacy
By Conni Koury, contributing writer
December 16, 2022
Thea Pharma Receives FDA Approval for Iyuzeh Preservative-free Latanoprost
By Jennifer Ford, senior managing editor
September 1, 2022
From the Editor: Five Years of Glaucoma Physician
By Nathan M. Radcliffe, MD
September 1, 2022
Phase 2 Data Favorable for QLS-101 Safety, Efficacy
By Conni Koury, contributing writer
March 1, 2022
Study: Durysta Bimatoprost Implant Effective for OAG, Ocular Hypertension
By Conni Koury, contributing writer
March 1, 2022
COVID-19's Effect on Patient Adherence to Ocular Hypotensive Medication Studied
By Conni Koury, contributing writer
June 1, 2020
Nicox Clinical Trial Update
By Jerry Helzner, contributing editor
June 1, 2020
Study: Raising Eye Pressure Causes Glaucoma
By Jerry Helzner, contributing editor
March 1, 2020
Aerpio Has Good Early Data in Tie2 Regulation
By Jerry Helzner, contributing editor
Advertisement
Recommendations
Advertisement